We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in Adults: What Else Do We Need to Know About How to Use Them?
- PMID: 39099081
- DOI: 10.1093/cid/ciae362
We Have Effective Respiratory Syncytial Virus Vaccines to Prevent Disease in Adults: What Else Do We Need to Know About How to Use Them?
Keywords: older and high-risk adults; respiratory syncytial virus; vaccines.
Conflict of interest statement
Potential conflicts of interest. A. B. reports grant funding from Moderna, Cyanvac, Pfizer, Vaccitech, and Merck and serves as a consultant for Novavax and GlaxoSmithKline. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.Clin Infect Dis. 2024 Oct 15;79(4):1088-1098. doi: 10.1093/cid/ciae365. Clin Infect Dis. 2024. PMID: 39099085 Free PMC article. Clinical Trial.
-
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364. Clin Infect Dis. 2024. PMID: 39099093 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical